Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2

February 2017 | Volume 16 | Issue 2 | Original Article | 147 | Copyright © February 2017


Kristina C. Duffin MD MS,a Kim A. Papp MD PhD,b Jerry Bagel MD,c Eugenia Levi PharmD BCPS,d Rongdean Chen PhD,d and Alice B. Gottlieb MD PhDe

aUniversity of Utah, Salt Lake City, UT bProbity Medical Research and K Papp Clinical Research, Waterloo, ON, Canada cPsoriasis Treatment Center of Central New Jersey, East Windsor, NJ dCelgene Corporation, Summit, NJ eTufts University School of Medicine, Boston, MA

these findings, further research is warranted to evaluate this new assessment tool in prospective studies that include patients with more moderate disease, in whom PASI may be less sensitive to therapeutic change, and to understand the clinical relevance with respect to change in disease severity.

ACKNOWLEDGMENTS

The authors would like to thank Irina Khanskaya, John Marcsisin, Claire Barcellona (clinical), Zuoshun Zhang (statistics), Monica Bilbault, Dale McElveen (clinical operations), Marlene Kachnowski (data management), Ann Marie Tomasetti, Trisha Zhang (programming), and Kamal Shah (safety) of Celgene Corporation for their contributions to the study and/or the manuscript. The authors received editorial support in the preparation of the manuscript from Kathy Covino, PhD, of Peloton Advantage LLC, funded by Celgene Corporation. The authors, however, directed and are fully responsible for all content and editorial decisions for this manuscript.

DISCLOSURES

Kristina C. Duffin MD MS has been a consultant, steering committee member, and/or advisory board member for, and/or has received grants and/or honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Cento- cor/Janssen, Eli Lilly, Novartis, P zer, Regeneron, Stiefel, and XenoPort. Kim Papp MD PhD has been a consultant, speakers bureau member, scientific officer, steering committee member, and/or advisory board member for, and/or has received grants and/or honoraria from Abbott, Actelion, Akesis, Akros, Alza, Amgen, Anacor, Astellas, AstraZeneca, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite, Celgene Corporation, Celtic, Centocor, Cipher, Dermira, Dow Pharma, Eli Lilly, EMD Serono, Forward Pharma, Funxional Therapies, Galderma, GlaxoSmith- Kline, Janssen, Kirin, Kyowa, Lypanosys, MedImmune, Merck, Mitsubishi Pharma, Novartis, P zer,Takeda, UCB, Valeant, Vertex. Jerry Bagel MD has received honoraria as an investigator, speaker, and/or advisor for AbbVie, Celgene Corporation, Eli Lilly, and LEO Pharma, and is the owner of the Psoriasis Treat- ment Center. Eugenia Levi PharmD BCPS and Rongdean Chen PhD are employees of Celgene Corporation. Alice B. Gottlieb, MD, PhD has consulting/advisory board agreements with Amgen Inc., Astellas, Akros, Centocor (Jans- sen), Inc., Celgene Corporation, Bristol-Myers Squibb Co., Beiersdorf, Inc., Abbott Labs (AbbVie), TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor Ltd., Incyte, P zer, Can-Fite, Lilly, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Life, GlaxoSmithKline, XenoPort, Catabasis, Meiji Seika Pharma Co., Ltd, Takeda, Mitsubishi Tanabe Pharma Development America, Inc., Genentech, Baxalta, and Kineta One. She is the recipient of research/educational Grants paid toTufts Medical Center from Centocor (Janssen), Amgen, Abbott (AbbVie), Novartis, Celgene Corporation, P zer, Lilly, Coronado, Levia, Merck, XenoPort, Dermira, and Baxalta. These studies were sponsored by Celgene Corporation, Summit, NJ, USA.

REFERENCES

  1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850. 
  2. Kristina Duf n MD MS,a Kim A. Papp MD PhD,b Jerry Bagel Spuls PI, Lecluse LL, Poulsen ML, et al. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933-943. 
  3. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244. 
  4. Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2)10-16. 
  5. Walsh JA, McFadden M, Woodcock J, et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol. 2013;69(6):931-937. 
  6. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583-1590. 
  7. Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016- 2029. 
  8. Otezla [package insert]. Summit, NJ: Celgene Corporation; December 2015. 
  9. Otezla [summary of product characteristics]. Uxbridge, UK: Celgene Europe Ltd; 2015. 
  10. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Ef cacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1]). J Am Acad Dermatol. 2015;73(1):37-49. 
  11. Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ES- TEEM 2). Br J Dermatol. 2015;173(6):1387-1399. 
  12. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practi- cal measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216. 
  13. Chiesa Fuxench ZC, Callis DK, Siegel M, et al. Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA) for objectively evaluating disease severity in patients with plaque psoriasis. J Am Acad Dermatol. 2015;73(5):868-870. 
  14. Walsh J. Comparative assessment of PASI and variations of PGAxBSA as measures of psoriasis severity in a clinical trial of moderate to severe psoria- sis [poster 1830]. Presented at: Annual Meeting of the American Academy of Dermatology; March 20-24, 2015; San Francisco, CA. 
  15. Gelfand JM, Wan J, Callis Duf n K, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol. 2012;148(4):487-494. 

AUTHOR CORRESPONDENCE

Kirstina C. Duffin MD MS kristina.duffin@hsc.utah.edu
Close Menu